Context Therapeutics Inc. reported that the FDA has granted Fast Track designation to CTIM-76, its investigational Claudin 6 x CD3 T cell engaging bispecific antibody, for treating platinum-resistant ovarian cancer in patients who have received all standard therapies.
CTIM-76 is being studied in a Phase 1 clinical trial in CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers, assessing safety, tolerability, pharmacokinetics and anti-tumor activity. The company expects interim Phase 1a data for CTIM-76 in June 2026, highlighting a near-term clinical milestone for this program.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.